Apmonia Therapeutics key facts
as of Oct 2026- Developer of peptide-based biotechnology designed to provide therapeutic strategies for multiple types of cancer.
- Apmonia Therapeutics is valued at approximately $26.8M as of Oct 2026 (last reported valuation).
- It has raised $23.9M; the latest was Later Stage VC ($11.7M) in Feb 2026.
- Notable investors include Bpifrance, European Innovation Council, Capital Grand Est, Angels Santé, Business Angels Marne Ardennes — 12 tracked in total.
- Status: Privately Held (backing).
Apmonia Therapeutics's last reported valuation, Oct 2025. Nothing priced has surfaced since.
- ·The complete investor list: 12 names
- ·Watch Apmonia Therapeutics: the Monday email on marks, rounds and moves
Apmonia Therapeutics funding rounds
No funding rounds for Apmonia Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Apmonia Therapeutics
12+Apmonia Therapeutics valuation
Apmonia Therapeutics's last reported valuation was $26.8 million in Oct 2025. No priced round, secondary trade or fund mark has surfaced since.
Apmonia Therapeutics investors
12 investors are on record for Apmonia Therapeutics, including Bpifrance, European Innovation Council, Capital Grand Est and Angels Santé.
About Apmonia Therapeutics
Developer of peptide-based biotechnology designed to provide therapeutic strategies for multiple types of cancer. The company focuses on creating drugs to treat glioblastoma, ovarian, colorectal, and pancreatic cancer, targeting the tumor microenvironment, and offers new therapeutic perspectives, particularly for the treatment of solid tumors, enabling patients to help fight cancer and helping researchers to develop personalized immunotherapy approaches combining a proprietary therapeutic peptide.
- Sector
- Healthcare
- HQ
- Reims, France
- Founded
- 2019
- Employees
- 15
- Website
- apmonia-therapeutics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.